BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile o
Adverse events reported by at least 3% of subjects in either group, by system organ, regardless of relationship to study product. The number of subjects reporting a specific adverse event and the numb
Supplementary Material Table S1: The 65 PT entries that simultaneously satisfied the four methods of disproportionality analysis with positive signal strength in FAERS. The PT entries are categorized